Most Read Articles
Elaine Soliven, 3 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Stephen Padilla, 3 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 2 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.

HRQoL lower in kids with functional constipation

30 Oct 2019

Children with functional constipation suffer from compromised health-related quality of life (HRQoL), reports a recent meta-analysis.

Accessing the databases of Pubmed, PsycINFO and Embase, researchers retrieved 19 studies, corresponding to a cumulative sample of 2,344 children (aged 2–18 years; 48 percent female). Papers including patients with organic causes of constipation and that assessed HRQoL only after therapeutic treatment were ineligible for the analysis.

Thirteen of the included studies used the Paediatric Quality of Life Inventory and were eligible for meta-analysis. The resulting mean sample size-weighted pooled mean HRQoL score was 65.6. This was significantly lower than that in reference healthy populations (86.1; p<0.001).

Factors associated with quality of life in children with functional constipation included psychological maladjustment, longer disease duration and discomforting symptoms in the upper and lower gastrointestinal tract.

Parental factors likewise emerged as reliable predictors of child HRQoL. Maternal psychological distress and caregiver HRQoL, for instance, were both correlated with the child’s own HRQoL. The same was true for a poor relationship between the caregiver and the child, low socioeconomic status of the family, parental stress, and low educational level of the parents.

“We … recommend the use of HRQoL instruments in both research and clinical settings to assess the efficacy of treatments and follow-up,” said researchers. “We also identified modifiable risk factors, such as parental distress and duration of symptoms that may affect HRQoL of children with functional constipation.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 3 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Stephen Padilla, 3 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 2 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.